Feraheme

Iron Deficiency Anemia, Chronic Kidney Disease
Treatment
4 FDA approvals
20 Active Studies for Feraheme

What is Feraheme

FerumoxytolThe Generic name of this drug
Treatment SummaryFerumoxytol is an intravenous drug used to treat iron deficiency anemia in adults with chronic kidney disease. It is made up of tiny particles of iron oxide that are coated in a sugar shell and dissolved in a solution that can be injected quickly.
Feridexis the brand name
image of different drug pills on a surface
Feraheme Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Feridex
Ferumoxytol
2008
3

Approved as Treatment by the FDA

Ferumoxytol, otherwise known as Feridex, is approved by the FDA for 4 uses including Chronic Kidney Disease and Chronic Kidney Disease (CKD) .
Chronic Kidney Disease
Chronic Kidney Disease (CKD)
Iron Deficiency Anemia (IDA)
Iron Deficiency Anemia

Effectiveness

How Feraheme Affects PatientsFerumoxytol is a drug that helps increase the amount of iron in the body, which can help treat anemia. Studies have shown that Ferumoxytol is more effective than oral iron in helping to boost hemoglobin, serum ferritin, and transferrin saturation. It can also be used as a contrast agent for magnetic resonance imaging (MRI) studies. This drug helps increase the time frame to acquire data during MRI studies and it slowly crosses the blood-brain barrier. Iron is an important part of many enzymes and proteins in the body, and its deficiency can lead to anemia and decreased oxygen delivery
How Feraheme works in the bodyFeraheme is a drug made up of an iron core, coated in a carbohydrate shell. This shell allows it to move around the body without interacting with other molecules. When it reaches macrophages in the liver, spleen, and bone marrow, the shell is broken down and the iron is released. The iron can then be stored as ferritin or transported to the red blood cells to make hemoglobin. Iron is also important for many other body processes, such as mitochondrial activity and metabolic functions. Feraheme can replace iron stores without causing many side effects. Additionally, it can be used in MRI scans to dark

When to interrupt dosage

The proposed measure of Feraheme is contingent upon the diagnosed state. The quantity of dosage fluctuates, in line with the method of delivery (e.g. Injection - Intravenous or Solution) featured in the following table.
Condition
Dosage
Administration
Chronic Kidney Disease
, 30.0 mg/mL, 0.051 mg/mL, 51.0 mg/mL, 11.2 mg/mL
, Intravenous, Solution, Solution - Intravenous, Injection, Injection - Intravenous
Iron Deficiency Anemia
, 30.0 mg/mL, 0.051 mg/mL, 51.0 mg/mL, 11.2 mg/mL
, Intravenous, Solution, Solution - Intravenous, Injection, Injection - Intravenous

Warnings

There are 20 known major drug interactions with Feraheme.
Common Feraheme Drug Interactions
Drug Name
Risk Level
Description
Technetium Tc-99m oxidronate
Major
Ferumoxytol can cause a decrease in the absorption of Technetium Tc-99m oxidronate resulting in a reduced serum concentration and potentially a decrease in efficacy.
3-Aza-2,3-Dihydrogeranyl Diphosphate
Minor
Ferumoxytol can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium Phosphate
Minor
Ferumoxytol can cause a decrease in the absorption of Calcium Phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Calcium phosphate dihydrate
Minor
Ferumoxytol can cause a decrease in the absorption of Calcium phosphate dihydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Dipotassium phosphate
Minor
Ferumoxytol can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Feraheme Toxicity & Overdose RiskFeraheme may cause serious allergic reactions, including anaphylaxis and anaphylactoid reactions. Symptoms of a mild allergic reaction, such as itching, rash, hives, or wheezing, have been reported in 3.7% of those who use the drug. No evidence of cancer or fertility problems have been linked to Feraheme. Taking Feraheme can also cause low blood pressure, iron overload, and changes to MRI imaging that may last for up to 12 weeks after the last dose. It is important to monitor patients for signs of allergic reaction and limit administration of the drug only when personnel
image of a doctor in a lab doing drug, clinical research

Feraheme Novel Uses: Which Conditions Have a Clinical Trial Featuring Feraheme?

118 active clinical trials are presently being conducted to assess the utility of Feraheme in the management of Iron deficiency anemia.
Condition
Clinical Trials
Trial Phases
Iron Deficiency Anemia
7 Actively Recruiting
Phase 3, Phase 4, Phase 2, Not Applicable
Chronic Kidney Disease
102 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 4, Phase 3, Early Phase 1

Feraheme Reviews: What are patients saying about Feraheme?

5Patient Review
1/10/2015
Feraheme for Anemia from Inadequate Iron
Feraheme has been an absolute lifesaver for me. I've been getting infusions weekly to monthly for the past seven years and it's kept my iron levels stable. I highly recommend this treatment to anyone who is struggling with iron deficiency.
5Patient Review
4/7/2015
Feraheme for Anemia from Inadequate Iron
I have severe anemia and my first infusion was with Dextran, where i had no side affects whatsoever, and it took about 1.5 weeks to feel the effects of energy; it lasted about 3.5 months. The second infusion was yesterday with Feraheme. Shorter infusion time, no side effects, hope it works the same. The second dose will be on Monday, but so far so good.
5Patient Review
5/21/2022
Feraheme for Anemia in Chronic Kidney Disease
I had a great experience with this medication and saw results very quickly. I would highly recommend it to others who are struggling with similar issues.
5Patient Review
4/5/2015
Feraheme for Anemia from Inadequate Iron
I didn't have any bad reactions. If anything, I felt like I had more energy and generally felt good while taking this medication.
4.3Patient Review
1/5/2015
Feraheme for Anemia from Inadequate Iron
No adverse affects that I could tell; you go in, get an IV, sit for ten minutes, and then leave. I've been struggling to improve my anemia for years without any success, but this finally seems to be working.
4Patient Review
5/5/2014
Feraheme for Anemia from Inadequate Iron
I have only had positive experiences with this treatment, despite all of the negative reviews I've read.
3Patient Review
3/16/2015
Feraheme for Anemia from Inadequate Iron
I had my first IV infusion four days ago. There was no swelling or irritation at the site. However, since the treatment I have suffered from severe headaches and bone/muscle pain, as well as a small rash on both legs. These side effects are unpleasant, but hopefully they will go away soon.
3Patient Review
4/16/2015
Feraheme for Anemia from Inadequate Iron
I had some chest pain after the first transfusion, but it was determined that my vitals were all good and I was sent home. After the second transfusion, I just felt really tired and drowsy. No change in energy levels, unfortunately.
2.7Patient Review
2/9/2022
Feraheme for Anemia from Inadequate Iron
I have been prescribed feraheme a few times for anemia, but it unfortunately doesn't help my body store the iron. A few months later, my anemia got worse. Venofer has kept my iron level at normal ranges for over two years now though.
2.3Patient Review
11/15/2016
Feraheme for Anemia from Inadequate Iron
I had the injection in April and experienced no issues until a few months later when I started to feel short of breath, have low blood pressure, and Bradycardia. My thyroid TSH levels also spiked. The only thing that changed was the Feraheme injection, so in my opinion, it's the likely culprit. However, my doctor wants me to do it again because she thinks my ferritin should be around 100 (it's currently at 69). I'd rather just stick with iron supplements from now on.
1.7Patient Review
5/28/2015
Feraheme for Anemia from Inadequate Iron
I had a very severe allergic reaction after taking this medication. I thought I was going to die. The next night, I tried Vonofer and had a much better experience.
1.3Patient Review
11/3/2018
Feraheme for Anemia from Inadequate Iron
After being a vegetarian for five years, my iron levels started dropping. My GI doctor discovered this during a routine blood check and referred me to a hematologist. Unfortunately, the feraheme infusion I received led to anaphylaxis within seconds. Needless to say, I won't be getting any more iron infusions...
1.3Patient Review
12/3/2015
Feraheme for Anemia due to Kidney Failure
Unfortunately, this caused anaphylaxis for me. The scariest thing ever! I don't know if it would have worked because I can never have the follow up doses needed.
1Patient Review
9/12/2015
Feraheme for Anemia from Inadequate Iron
My 92 year old father was prescribed this by his kidney specialist. However, after severe diarrhea, joint pain, and low blood pressure started just a few hours after the treatment, we decided to cancel his next appointment.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about feraheme

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Feraheme?

"You may experience dizziness, fainting, low blood pressure, injection site reactions, nausea, vomiting, stomach pain, and diarrhea."

Answered by AI

How long does Feraheme infusion last?

"Feraheme will be injected into your vein intravenously (IV) by your healthcare provider. The infusion will last for at least 15 minutes. You will receive two doses of Feraheme, 3 to 8 days apart. Your healthcare provider will monitor you during the infusion and for at least 30 minutes after you receive the medication."

Answered by AI

What is Feraheme infusion?

"Feraheme is a medicine that replaces iron in the body. It works by providing more iron so that the body can make more red blood cells. These blood cells carry oxygen throughout the body. Feraheme is given as an intravenous infusion by a health care professional."

Answered by AI

What happens after Feraheme infusion?

"If you experience any of the following adverse reactions after taking a medication from AMAG Pharmaceuticals, you should report it by calling 1-877-411-2510 or emailing medinfoUS@covispharma.com. The most common adverse reactions are diarrhea, headache, nausea, dizziness, hypotension, constipation, and peripheral edema."

Answered by AI

Clinical Trials for Feraheme

Image of Trinity Research Group in Dothan, United States.

Velocity pAVF System for Kidney Failure

18 - 80
All Sexes
Dothan, AL
This study will evaluate the Velocity Percutaneous Arteriovenous Fistula (pAVF) System, a new minimally invasive method for creating dialysis access. People with kidney failure often require dialysis, which depends on having a reliable arteriovenous fistula (AVF). Traditionally, AVFs are created with surgery, but surgery can involve incisions, longer recovery, and sometimes additional procedures before the AVF can be used. The Velocity System is designed to create an AVF through a small puncture in the skin using a catheter-based approach, without open surgery. This pivotal study will assess how safe the procedure is and how well it works for patients who need dialysis. The study will take place at multiple centers in the United States and will enroll adults with kidney failure who are candidates for fistula creation. Participants will undergo the Velocity procedure and then be followed closely with exams, ultrasounds, and dialysis assessments for up to five years. Taking part is voluntary. Patients may benefit from a less invasive approach to dialysis access, but the main goal is to collect information that could improve future care for people with kidney failure.
Recruiting
Has No Placebo
Trinity Research Group (+4 Sites)Venova Medical
Image of University of Alabama at Birmingham in Birmingham, United States.

Empagliflozin for Chronic Kidney Disease

2 - 17
All Sexes
Birmingham, AL
This study is open to children aged 2 to 17 with chronic kidney disease (CKD). The purpose of this study is to find out if a medicine called empagliflozin helps children and adolescents with CKD. Other goals of the study are to find out how empagliflozin is tolerated and handled by the body in children and adolescents with CKD. Participants are put into 2 groups randomly, which means by chance. One group takes empagliflozin and the other group takes placebo. Placebo looks like empagliflozin but does not contain any medicine. Participants are twice as likely to be in the empagliflozin group. Participants take empagliflozin or placebo as tablets once a day for 6 months. After 6 months, participants in both groups take empagliflozin as tablets once a day for 1 year. Participants are in the study for a little over a year and a half. During this time, they visit the study site about 15 times and get at least 5 phone or video calls from the site staff. At the visits, the doctors take blood and urine samples from the participants. The doctors also regularly check participants' health and take note of any unwanted effects.
Phase 3
Waitlist Available
University of Alabama at Birmingham (+33 Sites)Boehringer Ingelheim
Image of Centre hospitalier affilié universitaire régional de Trois-Rivières in Trois-Rivières, Canada.

Endoscopic Evaluation for Iron-Deficiency Anemia

18 - 90
All Sexes
Trois-Rivières, Canada
This is a single-center, randomized pilot study evaluating the feasibility and safety of two management strategies for patients on antithrombotic therapy who present with obscure gastrointestinal bleeding (OGIB). Participants will be randomized to either repeated endoscopic evaluations or a conservative medical approach with limited testing. The study aims to assess whether conservative management yields similar clinical outcomes and quality of life compared to standard repeated endoscopic procedures. Results will inform the design of a larger trial and address the current lack of guidelines for managing recurrent iron-deficiency anemia in this patient population.
Recruiting
Has No Placebo
Centre hospitalier affilié universitaire régional de Trois-RivièresÉva Mathieu, PhD
Have you considered Feraheme clinical trials? We made a collection of clinical trials featuring Feraheme, we think they might fit your search criteria.Go to Trials
Have you considered Feraheme clinical trials? We made a collection of clinical trials featuring Feraheme, we think they might fit your search criteria.Go to Trials
Image of Foothills Medical Centre in Calgary, Canada.

Decision Aid for Chronic Kidney Disease and Coronary Artery Disease

18+
All Sexes
Calgary, Canada
Many people with kidney disease also have heart disease. The procedures used to diagnose and treat heart disease (e.g., angiograms, angioplasty, or surgery) can improve symptoms and cardiovascular outcomes, but pose greater risks of kidney complications for people with chronic kidney disease. It's therefore important that patients with kidney disease and their health care providers understand the benefits versus risks of these procedures and use that information to make informed decisions regarding their health care. Prior research done with patients with kidney disease and their health care providers has led to the develop of a decision aid designed to help doctors provide personalized information on the benefits versus risks of having a heart procedure, as well as help patients communicate their own values and preferences to their doctor. This information is crucial for shared decision making, as previous research has shown that preferences and values vary for individual patients with kidney diseases, and should be incorporated into the decision-making process for heart disease management. The decision aid, called "My Heart Care and CKD", supports shared decision-making between patients with kidney disease and heart their care providers. This trial will implement and evaluate this decision aid within cardiovascular care in a pilot trial in Canada.
Waitlist Available
Has No Placebo
Foothills Medical Centre (+1 Sites)Matthew T James, MD
Have you considered Feraheme clinical trials? We made a collection of clinical trials featuring Feraheme, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security